GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper(II)) has been used for decades in low-concentration topical cosmetics with a generally favorable tolerability record, but there is almost no published human adverse-event data especially for injectable or systemic research use
Understanding dual-action GLP-1/GIP therapy Tirzepatide is a dual receptor agonist that activates both GLP-1 and GIP receptors
A patent thicket is exactly what it sounds like: a dense cluster of patents around a single drug product that individually might not survive challenge but collectively deter generic entrants because the cost of litigating a dozen patents simultaneously is prohibitive
There are many myths about diabetes such as the belief that overeating sugar causes diabetes or that people with diabetes cant eat sweets
Therefore, future studies incorporating quantitative imaging or biopsy-based assessments are warranted to better clarify the hepatic effects of incretin-based therapies
15.Abramson A, Halperin F, Kim J, Traverso G